Analyst Price Targets — ADMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 11:23 am | — | Mizuho Securities | $17.00 | $8.87 | TheFly | Adma Biologics price target lowered to $17 from $20 at Mizuho |
| June 10, 2026 11:25 am | Ryan Deschner | Raymond James | $21.00 | $8.12 | TheFly | Adma Biologics resumed with an Outperform at Raymond James |
| May 7, 2026 10:40 am | Gary Nachman | Canaccord Genuity | $18.00 | $10.08 | TheFly | Adma Biologics price target lowered to $18 from $21 at Canaccord |
| April 20, 2026 8:20 pm | — | Canaccord Genuity | $21.00 | $10.88 | TheFly | Adma Biologics initiated with a Buy at Canaccord |
| April 13, 2026 2:35 pm | Anthony Petrone | Mizuho Securities | $24.00 | $10.33 | TheFly | Adma Biologics price target lowered to $24 from $30 at Mizuho |
| October 14, 2024 6:58 am | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $17.15 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on ADMA Biologics (ADMA) |
| June 20, 2024 6:47 am | Anthony Petrone | Mizuho Securities | $14.00 | $10.62 | StreetInsider | ADMA Biologics (ADMA) PT Raised to $14 at Mizuho |
| January 3, 2023 6:14 am | — | H.C. Wainwright | $4.50 | $3.88 | Benzinga | HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $4.5 |
| November 10, 2022 10:24 am | — | Mizuho Securities | $6.00 | $3.05 | Benzinga | Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $6 |
| July 25, 2022 6:44 am | — | H.C. Wainwright | $4.00 | $2.17 | Benzinga | HC Wainwright & Co. Maintains Buy on ADMA Biologics, Lowers Price Target to $4 |
Latest News for ADMA
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) PR Newswire
PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.
New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and…
Philadelphia, Pennsylvania--(Newsfile Corp. - August 24, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its…
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA PR Newswire
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ADMA.
U.S. House Trading
No House trades found for ADMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.